Geron (NASDAQ:GERN) Trading Down 4.3%

Shares of Geron Co. (NASDAQ:GERN) traded down 4.3% during trading on Monday . The company traded as low as $3.73 and last traded at $3.76. 3,513,155 shares were traded during mid-day trading, a decline of 69% from the average session volume of 11,213,341 shares. The stock had previously closed at $3.93.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on the company. The Goldman Sachs Group lifted their target price on Geron from $4.00 to $5.00 and gave the company a “buy” rating in a research note on Friday, March 15th. Wedbush reissued an “outperform” rating and issued a $6.00 price target on shares of Geron in a report on Wednesday, April 10th. TD Cowen assumed coverage on shares of Geron in a research report on Monday, April 29th. They set a “buy” rating and a $10.00 price target on the stock. Needham & Company LLC reiterated a “buy” rating and issued a $5.00 price objective on shares of Geron in a research report on Thursday, May 2nd. Finally, Robert W. Baird downgraded Geron from an “outperform” rating to a “neutral” rating and set a $4.50 price objective on the stock. in a report on Tuesday, April 30th. One analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $6.10.

Geron Trading Down 1.6 %

The company has a market capitalization of $2.26 billion, a PE ratio of -10.89 and a beta of 0.55. The business’s 50-day simple moving average is $3.20 and its two-hundred day simple moving average is $2.42. The company has a current ratio of 3.67, a quick ratio of 3.67 and a debt-to-equity ratio of 0.03.

Geron (NASDAQ:GERN) last issued its quarterly earnings results on Wednesday, February 28th. The biopharmaceutical company reported ($0.09) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.10) by $0.01. The company had revenue of $0.02 million for the quarter, compared to analysts’ expectations of $0.06 million. Geron had a negative return on equity of 68.16% and a negative net margin of 38,730.00%. The firm’s revenue for the quarter was down 77.7% on a year-over-year basis. During the same period last year, the firm earned ($0.10) EPS. On average, analysts predict that Geron Co. will post -0.33 earnings per share for the current year.

Hedge Funds Weigh In On Geron

Several large investors have recently added to or reduced their stakes in the company. Vishria Bird Financial Group LLC increased its holdings in Geron by 17.7% in the first quarter. Vishria Bird Financial Group LLC now owns 24,265 shares of the biopharmaceutical company’s stock valued at $80,000 after purchasing an additional 3,650 shares during the last quarter. Moody National Bank Trust Division grew its stake in Geron by 4.0% in the 4th quarter. Moody National Bank Trust Division now owns 132,053 shares of the biopharmaceutical company’s stock valued at $279,000 after buying an additional 5,079 shares during the last quarter. Amalgamated Bank lifted its holdings in shares of Geron by 9.0% during the third quarter. Amalgamated Bank now owns 69,122 shares of the biopharmaceutical company’s stock worth $147,000 after buying an additional 5,681 shares in the last quarter. Teacher Retirement System of Texas boosted its stake in shares of Geron by 4.7% in the third quarter. Teacher Retirement System of Texas now owns 130,096 shares of the biopharmaceutical company’s stock valued at $276,000 after buying an additional 5,880 shares during the period. Finally, China Universal Asset Management Co. Ltd. grew its stake in Geron by 101.3% during the third quarter. China Universal Asset Management Co. Ltd. now owns 13,426 shares of the biopharmaceutical company’s stock worth $28,000 after buying an additional 6,757 shares in the last quarter. Institutional investors and hedge funds own 73.71% of the company’s stock.

Geron Company Profile

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.